Tadalafil for sale selling, general and administrative expenses increased $33. 9 million over the 2002 third quarter, to $49. Tadalafil for sale 1 million for the three months ended September 30, 2003. Lilly tadalafil for sale icos' 2005 second quarter net loss narrowed to $1. 7 million, compared to $41. 7 million in the tadalafil for sale 2005 first quarter.
Regulatory decision regarding Cialis late tadalafil for sale in 2003. "More and more doctors and patients are experiencing Cialis and making it their product of choice due to its extended duration of action and lack of food interaction. Total revenue was $12.

1 million in the third quarter of 2003, compared to $22. 2 million in the third quarter of tadalafil for sale 2002. In preparation for the launch of Cialis in the U. , ICOS has hired and deployed approximately 165 sales representatives that will, in close coordination with their Lilly counterparts, promote Cialis to urologists and Tadalafil for sale other physicians.

Revenue from licenses tadalafil for sale of technology was $2. 2 million in 2004 compared to $37. 0 million in tadalafil for sale 2003. Eli Lilly and Company, a leading innovation-driven corporation, is developing a tadalafil for sale growing portfolio of best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. In Lilly ICOS territories, sales totaled $421. 7 million tadalafil for sale for the year, including $206.
6 million in the U. 9 million in Europe and $37. 2 tadalafil for sale million in Canada and Mexico combined. In the United States, Cialis is currently under review by the U.
Cialis is currently under regulatory review by tadalafil for sale the U. Contract manufacturing revenue increased $3. 9 million from the third quarter of 2002, to $6. 8 million in the third quarter of 2003, tadalafil for sale reflecting greater utilization of available manufacturing capacity for third-party contracts and additional development services provided under our current agreements. 5, 2003 ICOS Corporation (Nasdaq:ICOS) (ICOS or the Company) today summarized recent events and released its financial results for the three and six months ended June 30, 2003. About Lilly ICOS LLC Lilly ICOS LLC, a joint venture between ICOS Corporation and Eli Lilly and Company, is marketing Cialis in the European Union, and pursuing regulatory approvals in North America for the treatment of sexual dysfunction. Total revenue was $26. 7 million in the tadalafil for sale second quarter of 2003, compared to $22. 0 million in the second tadalafil for sale quarter of 2002. Certain of the matters discussed herein with respect to clinical studies and ICOS and Lilly's products may constitute forward-looking statements within the meaning of the tadalafil for sale private Securities Litigation Reform Act of 1995. Cialis Global Launch Update Since the launch in February 2003, Cialis has captured a significant share of unit (tablet) sales among the three PDE5 inhibitors (Cialis, Viagra and Levitra(R)(2) (vardenafil))(3).
The number of regulatory approvals for the drug continues to grow as well. New PDE-5 inhibitors need a unique clinical advantage to compete with the established products.